Lewes, DE -- (ReleaseWire) -- 02/18/2014 -- Diabetic Gastroparesis - Pipeline Review, H1 2014 report provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Gastroparesis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Gastroparesis. Diabetic Gastroparesis - Pipeline Review, Half Year is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team.
Inquiry for more information visit: http://www.marketresearchreports.com/global-markets-direct/diabetic-gastroparesis-pipeline-review-h1-2014
- A snapshot of the global therapeutic scenario for Diabetic Gastroparesis.
- A review of the Diabetic Gastroparesis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Diabetic Gastroparesis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Diabetic Gastroparesis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Diabetic Gastroparesis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Spanning over 51 pages, “Diabetic Gastroparesis - Pipeline Review, H1 2014” report covered 5 companies - Theravance, Inc., Evoke Pharma, Inc., Targacept, Inc., Cempra, Inc., Rhythm Pharmaceuticals.
Find All Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare
About Market Research Reports, Inc.
Market Research Reports, Inc. (http://www.MarketResearchReports.com) is the world's leading source for market research reports and market data. We provide you with the latest market research reports on global markets, key industries, leading companies, new products and latest industry analysis & trends.
For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter
Follow us on Twitter: https://twitter.com/MyMarketReports